Evaluation of Performance and Possible Clinical Impact of Rapid QMAC ‐ dRAST Antimicrobial Susceptibility Testing From Positive Blood Cultures in a Tertiary Hospital and Low Antimicrobial Resistance Setting
APMIS · 2026-11 · 134 (11)
DOI: 10.1111/apm.70279 ↗Kurz gefasst
Evaluationsstudie in der Zeitschrift APMIS, online erschienen am 06.11.2026. Verfasst von Dina Riihiaho und 3 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Microbiology, TYKS Laboratories, Turku University Hospital, Turku, Finland. Hauptthemen laut MEDLINE: Anti-Bacterial Agents, Bacteremia, Gram-Positive Bacteria, Gram-Negative Bacteria. Die Arbeit nennt 25 Literaturangaben.
Abstract (Originalsprache)
This study evaluated QMAC‐dRAST for rapid antimicrobial susceptibility testing from positive blood cultures in a low‐resistance setting by assessing analytical accuracy, detection of key resistance mechanisms and potential to shorten time to effective therapy. We tested 181 isolates and compared QMAC‐dRAST results with disc diffusion, resolving discrepancies by broth microdilution and calculating categorical agreement (CA) and error rates according to ISO 20776‐1:2019. We analyzed potential clinical impact among 128 patients with bacteremia. Categorical agreement was 92% for Gram‐negative and 91% for Gram‐positive bacteria, with very major errors in 7% and 28% of resistant isolates, respectively. Performance was limited for several key antibiotics: cefotaxime showed high very major error rates, piperacillin–tazobactam resistance was overestimated and meropenem resistance was underestimated. QMAC‐dRAST system correctly detected most critical resistance mechanisms, including all MRSA and VRE isolates and, after user interpretation, 90% of carbapenemase‐producing Enterobacterales. QMAC‐dRAST could have markedly shortened time to effective therapy in 8% of patients, but one false MRSA result risked inappropriate escalation of therapy. In this low‐resistance setting, QMAC‐dRAST offered modest benefit over rapid species identification, while suboptimal performance for key antibiotics, the absence of cefuroxime from the panel, and workflow challenges limited its utility without further optimization.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Clinical Microbiology, TYKS Laboratories, Turku University Hospital, Turku, Finland.
- Faculty of Medicine, University of Helsinki, Helsinki, Finland.
- Institute of Biomedicine, Faculty of Medicine, University of Turku, Turku, Finland.
ORCID-Profile: Dina Riihiaho, Ville Pirhonen, Annukka Pietikäinen, Kaisu Rantakokko-Jalava
Zitieren
APA
Riihiaho, D., Pirhonen, V., Pietikäinen, A., & Rantakokko-Jalava, K. (2026). Evaluation of Performance and Possible Clinical Impact of Rapid QMAC ‐ dRAST Antimicrobial Susceptibility Testing From Positive Blood Cultures in a Tertiary Hospital and Low Antimicrobial Resistance Setting. APMIS, 134(11). https://doi.org/10.1111/apm.70279
Vancouver
Riihiaho D, Pirhonen V, Pietikäinen A, Rantakokko-Jalava K. Evaluation of Performance and Possible Clinical Impact of Rapid QMAC ‐ dRAST Antimicrobial Susceptibility Testing From Positive Blood Cultures in a Tertiary Hospital and Low Antimicrobial Resistance Setting. APMIS. 2026;134(11). doi:10.1111/apm.70279
BibTeX
@article{Riihiaho2026,
author = {Riihiaho, Dina and Pirhonen, Ville and Pietikäinen, Annukka and Rantakokko-Jalava, Kaisu},
title = {Evaluation of Performance and Possible Clinical Impact of Rapid QMAC ‐ dRAST Antimicrobial Susceptibility Testing From Positive Blood Cultures in a Tertiary Hospital and Low Antimicrobial Resistance Setting},
journal = {APMIS},
year = {2026},
volume = {134},
number = {11},
doi = {10.1111/apm.70279}
}
EUVIMED